Articles, App Notes, Case Studies, & White Papers

  1. A New Specialist For Oligonucleotides With Advantages 12/16/2025

    Discover how hybrid silica technologies ensure stability and high resolution in IP-RP chromatography applications while protecting instrumentation from excessive wear and tear.

  2. Phase-Appropriate Approaches To Manufacturing And Testing 3/14/2025

    Accelerate the development of high-quality biopharmaceuticals by implementing phase-appropriate, risk-based manufacturing and testing strategies that ensure timely progression.

  3. Staying On Top Of Changing FDA Regulations To Avoid Clinical Holds 8/14/2023

    As the biotech industry has grown exponentially, so has the number of FDA clinical holds. Biotech companies need strategic planning to avoid or quickly resolve costly clinical holds.

  4. What's Next For ATMP Regulation In EMEA 10/20/2025

    Fragmented national regulations for pricing, customs, and reimbursement demand tailored supply chain strategies. Adapting to country-specific hurdles is essential for product integrity and patient access.

  5. Pancreatic Cancer: Global Clinical Trial Landscape (2024) 9/17/2024

    Explore the latest advancements in pancreatic cancer research with this comprehensive disease report, covering new treatments, clinical trials, and future innovations in care.

  6. Diffuse Large B-Cell Lymphoma- Global Clinical Trial Landscape 10/15/2024

    Explore the latest advancements in diffuse large B-cell lymphoma research, innovative therapies, and personalized care strategies shaping the future of treatment.

  7. Expanding Into New Fields Of “Cell-Grow-Culture” For mRNA Transfection 1/13/2023

    Learn about one path forward to navigate the pitfalls with mRNA transfection and a medium to assist in lentivirus-mediated transduction of human mesenchymal stromal/stem cells (hMSCs).

  8. Understanding The Microfluidic Platforms For Scaling Nanoparticle Production 10/13/2022

    Learn about the benefits of microfluidics for nanoparticle production over traditional methods as well as scaling nanoparticle production for clinical or industrial use.

  9. GMP Manufacturing Facility For Viral Vector Production 3/27/2018

    A new GMP production facility for viral vectors from nonadherent cell cultures alleviates concerns that there will be a restriction of speed in getting viral vector products from the laboratory to the patient.

  10. GMP-Source® And Phase-Appropriate Use For Early-Stage Clinical Trials 9/16/2021

    GMP-Source is a more robust, less rigid alternative to full cGMP production that mirrors nearly all of the oversight and quality standards of full cGMP production while relaxing certain commercial standards, helping companies overcome the hurdles that can stall early development.